✦ LIBER ✦

Antitumor activity of L6-ricin immunotoxin against the H2981-T3 lung adenocarcinoma cell line in vitro and in vivo

Book ID: 122032969
Publisher: Elsevier Science
Year: 1991
Tongue: English
Weight: 172 KB
Volume: 7
Category: Article
ISSN: 0169-5002
DOI: 10.1016/0169-5002(91)90115-M

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Inhibition of SIRT1 Signaling Sensitizes

Inhibition of SIRT1 Signaling Sensitizes the Antitumor Activity of Silybin against Human Lung Adenocarcinoma Cells In Vitro and In Vivo

✍ Liang, Z.; Yang, Y.; Wang, H.; Yi, W.; Yan, X.; Yan, J.; Li, Y.; Feng, Y.; Yu, S 📂 Article 📅 2014 🏛 American Association for Cancer Research 🌐 English ⚖ 690 KB

Antitumor activity of a polysaccharide f

Antitumor activity of a polysaccharide from longan seed on lung cancer cell line A549 in vitro and in vivo

✍ Wang, Hongmin; Zhang, Xiaohong; Li, Yuexia; Chen, Ruiying; Ouyang, Songyun; Sun, 📂 Article 📅 2014 🏛 S. Karger AG 🌐 English ⚖ 447 KB

The anti-tumor effects of CIK cells comb

The anti-tumor effects of CIK cells combined with docetaxel against drug-resistant lung adenocarcinoma cell line SPC-A1/DTX in vitro and in vivo

✍ Chen Long-bang; Liu Peng-ying 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 38 KB

Comparison of the antitumor activity of

Comparison of the antitumor activity of cisplatin, carboplatin, and iproplatin against established human testicular cancer cell lines in vivo and in vitro

✍ A. Harstrick; J. Casper; R. Guba; H. Wilke; H. Poliwoda; H. J. Schmoll 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 374 KB 👁 1 views

Antitumor activity of albendazole agains

Antitumor activity of albendazole against the human colorectal cancer cell line HT-29: in vitro and in a xenograft model of peritoneal carcinomatosis

✍ Mohammad H. Pourgholami; Javed Akhter; Lisa Wang; Ying Lu; David L. Morris 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 354 KB

Antitumor activity of the selective epid

Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa® (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo

✍ Ichiro Naruse; Tohru Ohmori; Yoko Ao; Hisao Fukumoto; Toshio Kuroki; Masatomo Mo 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 French ⚖ 216 KB 👁 1 views

## Abstract Selective tyrosine kinase inhibitors are regarded as promising antitumor agents for cancer treatment. Iressa® (ZD1839) is an orally active, selective EGFR‐TKI (epidermal growth factor receptor‐tyrosine kinase inhibitor) that blocks signal transduction pathways implicated in cancer cell